Prognostic influence of TNM staging and LDH levels in small cell carcinoma of the lung (SCCL)

Byhardt, Roger W.; Hartz, Arthur J.; Libnoch, Joseph A.; Hansen, Richard M.; Cox, James D.

doi:10.1016/0360-3016(86)90035-0

Cited by 33 publications

(16 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumour stage is known to be the most important prognostic factor of SCLC. ECOG performance status, age, gender and LDH are also known to correlate with the prognosis for SCLC [21][22][23]. Along with WBMTV, tumour staging (both conventional and TNM staging) and LDH level were also significant prognostic factors WBMTV whole-body metabolic tumour volume, SUV max maximum standardized uptake value, OS overall survival, PFS progression-free survival a The median values of WBMTV in each stage b The p values were produced using a one-way analysis of variance among groups c The p values were produced using a log-rank test for poor prognosis in this study.…”

Section: Discussionmentioning

confidence: 99%

Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer

Seo

Chong

et al. 2012

Eur J Nucl Med Mol Imaging

120

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer

Seo

Chong

et al. 2012

Eur J Nucl Med Mol Imaging

120

View full text Add to dashboard Cite

show abstract

“…The most important adverse prognostic factors in general are: ED and poor performance status. Furthermore, lactate dehydrogenase (LDH), male gender, paraneoplastic phenomena and involvement of the liver or the central nervous system seem to be correlated with a worse prognosis [6,7,17,18]. Furthermore, the response to third-line therapy seems to be dependent on the tumor response to first-line and second-line therapy [16].…”

Section: Discussionmentioning

confidence: 99%

Long-Term Survival of a Patient with Small Cell Lung Cancer after Nine Lines of Chemotherapy and Radiation

Gressner¹,

Popp²,

Mey³

et al. 2008

Onkologie

View full text Add to dashboard Cite

Background: Small cell lung cancer (SCLC) results in death within 1–2 months if left untreated. Although therapeutic standards only comprise first- and second-line chemotherapy due to poor prognosis, a subset of patients may warrant a trial of further chemotherapy, as demonstrated in the following case. Case Report: We present a 52-year-old man with confirmed anaplastic SCLC who survived 10 years while receiving 9 lines of chemotherapy including high-dose chemotherapy. Thoracic radiation, afterloading and radionuclide therapy supplemented the therapeutic management. Remarkably, he had two very long remission periods following topotecan. Conclusion: This case indicates that frequently repeated chemotherapy beyond second-line treatment in a subset of patients with limited-disease SCLC may result in long-term survival, even without ever achieving a complete remission. Close surveillance of responsiveness and appropriate in-time cytostatic treatment is proposed in the management of patients with SCLC who remain in good performance.

show abstract

“…The most important tumorrelated prognostic factor is the extent of disease, either LS-SCLC or ES-SCLC. In LS-SCLC, early-stage disease (TNM stage I) carries a favorable prognosis, while an elevated lactate dehydrogenase is considered unfavorable [7,9]. In ES-SCLC, the number of organ sites involved is inversely related to prognosis [6].…”

Section: Prognostic Factorsmentioning

confidence: 99%

Small Cell Lung Cancer: Have We Made Any Progress Over the Last 25 Years?

Lally¹,

Urbanic²,

Blackstock³

et al. 2007

The Oncologist

184

157

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Discuss the currently available SCLC treatment options.2. Describe the benefits of integrating thoracic radiotherapy into SCLC treatment.3. Identify the limitations of current SCLC treatment options and explain how future clinical trials are addressing these limitations.Access and take the CME test online and receive 1 AMA PRA Category 1 Credit ™ at CME.TheOncologist.com CME CME ABSTRACTTwenty-five years ago, small cell lung cancer was widely considered to be the next cancer added to the list of "curable cancers." This article attempts to summarize the progress made toward that goal since then. Clinical trials have provided landmarks in the therapy of limited-stage small cell lung cancer (LS-SCLC). These are: (a) the proof that thoracic radiation therapy adds to systemic chemotherapy, (b) the superiority of twice-daily radiation therapy over daily fractionation, and (c) the need for prophylactic central nervous system radiation (prophylactic cranial irradiation). Each of these innovations adds about 5%-10% to the overall survival rate. In extensive-stage disease, irinotecan plus cisplatin may be a possible alternative to the "standard" etoposide-cisplatin chemotherapy doublet, but there has been little progress otherwise. It is imperative that, whenever possible, patients be given the opportunity to participate in future clinical trials so that the survival for these patients can continue to improve. The Oncologist 2007;12:1096 -1104

show abstract

Prognostic influence of TNM staging and LDH levels in small cell carcinoma of the lung (SCCL)

Cited by 33 publications

References 12 publications

Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer

Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer

Long-Term Survival of a Patient with Small Cell Lung Cancer after Nine Lines of Chemotherapy and Radiation

Small Cell Lung Cancer: Have We Made Any Progress Over the Last 25 Years?

Contact Info

Product

Resources

About